We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta Genomics Identifies 49 microRNAs with Potential to Provide Molecular Biomarkers and Drug Target Candidates
News

Rosetta Genomics Identifies 49 microRNAs with Potential to Provide Molecular Biomarkers and Drug Target Candidates

Rosetta Genomics Identifies 49 microRNAs with Potential to Provide Molecular Biomarkers and Drug Target Candidates
News

Rosetta Genomics Identifies 49 microRNAs with Potential to Provide Molecular Biomarkers and Drug Target Candidates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rosetta Genomics Identifies 49 microRNAs with Potential to Provide Molecular Biomarkers and Drug Target Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics, Ltd. announces the publication of a study entitled, “Discovery of microRNAs and other small RNAs in solid tumors,” in the online edition of Nucleic Acid Research. The article was authored by Rosetta Genomics scientists including Dr. Eti Meiri and Einat Sitbon.

“So far this year, we have had six peer-reviewed articles published on our microRNA technology. These publications are a further demonstration of how Rosetta Genomics is maintaining a leadership position in the development of microRNAs for personalized medicine applications.”

“Our discovery of these new microRNAs gives us direct and exclusive access to 49 novel microRNAs, each one of which has the potential to be, alone or in combination with other microRNAs, a diagnostic biomarker, response biomarker or drug target. In addition, we have filed patent applications on each of these newly discovered microRNAs to enhance our expanding IP portfolio,” stated Kenneth A. Berlin, President and CEO of Rosetta Genomics.

“So far this year, we have had six peer-reviewed articles published on our microRNA technology. These publications are a further demonstration of how Rosetta Genomics is maintaining a leadership position in the development of microRNAs for personalized medicine applications.” The comprehensive database and proprietary technologies we have developed over the years are significant assets that allow us to lead in this area. They enable us to efficiently identify, extract, and quantify microRNAs, and transform them into commercially viable diagnostics, response biomarkers and therapeutics. This unrivaled set of capabilities allows us to harness the power of microRNAs as we work to improve healthcare worldwide,” added Mr. Berlin.
Advertisement